ClinicalTrials.gg

Immunoglobulin Light-chain Amyloidosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 239 studies for Immunoglobulin Light-chain Amyloidosis across more than 10 countries. 63 are recruiting or about to start. 115 of them are mainly about Immunoglobulin Light-chain Amyloidosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

Status

Completed
121
Recruiting
49
Terminated
23
Active, not recruiting
13
Withdrawn
10
Not yet recruiting
10

Phase

Phase 2
94
Phase 1
64
Phase 3
30
Early Phase 1
5
Phase 4
1

Where

United States
151
Italy
33
China
29
France
21
Germany
21
United Kingdom
19

Who develops what

Add Immunoglobulin Light-chain Amyloidosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 8 companies, 4 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Johnson & Johnson, AbbVie and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
daratumumabRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Daratumumab” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Daratumumab” · registered Aug 2026
  • NCT04304144 · AstraZeneca · Phase 2 · background · “Daratumumab” · registered Feb 2020
Johnson & Johnson64% of its industry studies22 studies
BortezomibRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Bortezomib” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Bortezomib” · registered Aug 2026
Johnson & Johnson33% of its industry studiesUS: off-patent, 15 generics marketedEU: off-patent, 3 generics authorized22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Cyclophosphamide” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Cyclophosphamide” · registered Aug 2026
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies
DexamethasoneRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Dexamethasone” · registered Aug 2026
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)22 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
linvoseltamabApproved: EU 2025☆ Track1 live phase-3 study: NCT07901725Regeneron Pharmaceuticals

The 1 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.Eque-cel CAR-T Therapy · Nanjing IASO Biotechnology Co., Ltd. · Phase 2 main aimNCT07055724 Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis — primary endpoint: Proportion of Patients Achieving Hematologic VGPR or Better by Day 90 · 17 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Immunoglobulin Light-chain Amyloidosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 4 open · Proteasome inhibitors 4 open · Alkylating agents 2 open · Antimetabolites 8 · Calcineurin inhibitors 3

Coming up

17studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger. 3 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (10%) take healthy volunteers.

Recruiting studies that take each age, of 49
AgeWomenMen
103 (6%)3 (6%)
1845 (92%)45 (92%)
3046 (94%)46 (94%)
4048 (98%)48 (98%)
5048 (98%)48 (98%)
6549 (100%)49 (100%)
7548 (98%)48 (98%)
8545 (92%)45 (92%)

Across all 239 studies, recruiting or not: 16% stop at 75 or younger and 5% at 65; 14% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Immunoglobulin Light-chain Amyloidosis studies take

Of 31 phase 2 interventional studies under Immunoglobulin Light-chain Amyloidosis, half reached primary completion within 58 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 258 mo43–89 · 31 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 239. Browse all 239 → or search them.